Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine
Purpose Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic...
Gespeichert in:
Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2014-04, Vol.88 (5), p.1085-1091 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1091 |
---|---|
container_issue | 5 |
container_start_page | 1085 |
container_title | International journal of radiation oncology, biology, physics |
container_volume | 88 |
creator | Folkert, Michael R., MD, PhD Bilsky, Mark H., MD Tom, Ashlyn K., BA Oh, Jung Hun, PhD Alektiar, Kaled M., MD Laufer, Ilya, MD Tap, William D., MD Yamada, Yoshiya, MD |
description | Purpose Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic radiosurgery (IG-SRS) may provide a more effective means of managing these lesions. Methods and Materials Patients with pathologically proven high-grade sarcoma metastatic to the spine treated with HF and SF IG-SRS were included. LC and overall survival (OS) were analyzed by the use of Kaplan-Meier statistics. Univariate and multivariate analyses were performed by the use of Cox regression with competing-risks analysis; all confidence intervals are 95%. Toxicities were assessed according to Common Terminology Criteria for Adverse Events, version 4.0. Results From May 2005 to November 11, 2012, 88 patients with 120 discrete metastases received HF (3-6 fractions; median dose, 28.5 Gy; n=52, 43.3%) or SF IG-SRS (median dose, 24 Gy; n=68, 56.7%). The median follow-up time was 12.3 months. At 12 months, LC was 87.9% (confidence interval [CI], 81.3%-94.5%), OS was 60.6% (CI, 49.6%-71.6%), and median survival was 16.9 months. SF IG-SRS demonstrated superior LC to HF IG-SRS (12-month LC of 90.8% [CI, 83%-98.6%] vs 84.1% [CI, 72.9%-95.3%] P =.007) and retained significance on multivariate analysis ( P =.030, hazard ratio 0.345; CI, 0.132-0.901]. Treatment was well tolerated, with 1% acute grade 3 toxicity, 4.5% chronic grade 3 toxicity, and no grade >3 toxicities. Conclusions In the largest series of metastatic sarcoma to the spine to date, IG-SRS provides excellent LC in the setting of an aggressive disease with low radiation sensitivity and poor prognosis. Single-fraction IG-SRS is associated with the highest rates of LC with minimal toxicity. |
doi_str_mv | 10.1016/j.ijrobp.2013.12.042 |
format | Article |
fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22416522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301613037206</els_id><sourcerecordid>1687674888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-55fb0faefe1dea50514aa61a258e19079694293782f00f95c5dffaf39013a72e3</originalsourceid><addsrcrecordid>eNqFkt-K1TAQxoMo7nH1DUQC3njTmqRN2t4Isuw_WFmwK3gXctLJ2dSepiapeHwH33nT7dELb4RAIPObbybzDUKvKckpoeJ9n9veu-2UM0KLnLKclOwJ2tC6arKC869P0YYUgmRFgk_QixB6QgilVfkcnbBSCCoE26Dft3PUbg8Bq7HDd-6n1TYesHEeXx0mZ7zS0bpRRegeidaOuwGyi-M7vt6rHWSXs-0S0Ebw4OIS0viz6qwLs9-BX_Va5VMlFfAniCqkY38lMRwdjveA28mO8BI9M2oI8Op4n6IvF-d3Z1fZze3l9dnHm0zzsowZ52ZLjAIDtAPFCaelUoIqxmugDaka0ZSsKaqaGUJMwzXvjFGmaNKkVMWgOEVvV10XopUhfRn0vXbjCDpKxkoqOGOJerdSk3ffZwhR7m3QMAxqBDcHSUVdiaqs6zqh5Ypq70LwYOTk7V75g6RELnbJXq52ycUuSZlMdqW0N8cK83YP3d-kP_4k4MMKQJrGDwt-aRZGDZ31S6-ds_-r8K-AHuxotRq-wQFC72Y_pklLKkNKkO2yMsvG0IIUFSOieADfmb8I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1687674888</pqid></control><display><type>article</type><title>Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Folkert, Michael R., MD, PhD ; Bilsky, Mark H., MD ; Tom, Ashlyn K., BA ; Oh, Jung Hun, PhD ; Alektiar, Kaled M., MD ; Laufer, Ilya, MD ; Tap, William D., MD ; Yamada, Yoshiya, MD</creator><creatorcontrib>Folkert, Michael R., MD, PhD ; Bilsky, Mark H., MD ; Tom, Ashlyn K., BA ; Oh, Jung Hun, PhD ; Alektiar, Kaled M., MD ; Laufer, Ilya, MD ; Tap, William D., MD ; Yamada, Yoshiya, MD</creatorcontrib><description>Purpose Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic radiosurgery (IG-SRS) may provide a more effective means of managing these lesions. Methods and Materials Patients with pathologically proven high-grade sarcoma metastatic to the spine treated with HF and SF IG-SRS were included. LC and overall survival (OS) were analyzed by the use of Kaplan-Meier statistics. Univariate and multivariate analyses were performed by the use of Cox regression with competing-risks analysis; all confidence intervals are 95%. Toxicities were assessed according to Common Terminology Criteria for Adverse Events, version 4.0. Results From May 2005 to November 11, 2012, 88 patients with 120 discrete metastases received HF (3-6 fractions; median dose, 28.5 Gy; n=52, 43.3%) or SF IG-SRS (median dose, 24 Gy; n=68, 56.7%). The median follow-up time was 12.3 months. At 12 months, LC was 87.9% (confidence interval [CI], 81.3%-94.5%), OS was 60.6% (CI, 49.6%-71.6%), and median survival was 16.9 months. SF IG-SRS demonstrated superior LC to HF IG-SRS (12-month LC of 90.8% [CI, 83%-98.6%] vs 84.1% [CI, 72.9%-95.3%] P =.007) and retained significance on multivariate analysis ( P =.030, hazard ratio 0.345; CI, 0.132-0.901]. Treatment was well tolerated, with 1% acute grade 3 toxicity, 4.5% chronic grade 3 toxicity, and no grade >3 toxicities. Conclusions In the largest series of metastatic sarcoma to the spine to date, IG-SRS provides excellent LC in the setting of an aggressive disease with low radiation sensitivity and poor prognosis. Single-fraction IG-SRS is associated with the highest rates of LC with minimal toxicity.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2013.12.042</identifier><identifier>PMID: 24661662</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Dose Fractionation ; Female ; HAZARDS ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; METASTASES ; Middle Aged ; MULTIVARIATE ANALYSIS ; Neoplasm Metastasis ; PATIENTS ; Prognosis ; Proportional Hazards Models ; RADIATION DOSES ; Radiation Injuries - diagnosis ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOSENSITIVITY ; Radiosurgery - adverse effects ; Radiosurgery - methods ; RADIOTHERAPY ; Radiotherapy Dosage ; RISK ASSESSMENT ; Sarcoma - mortality ; Sarcoma - pathology ; Sarcoma - surgery ; SARCOMAS ; Spinal Neoplasms - mortality ; Spinal Neoplasms - secondary ; Spinal Neoplasms - surgery ; SURGERY ; TOXICITY ; Treatment Outcome ; VERTEBRAE</subject><ispartof>International journal of radiation oncology, biology, physics, 2014-04, Vol.88 (5), p.1085-1091</ispartof><rights>2014</rights><rights>Copyright © 2014. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-55fb0faefe1dea50514aa61a258e19079694293782f00f95c5dffaf39013a72e3</citedby><cites>FETCH-LOGICAL-c544t-55fb0faefe1dea50514aa61a258e19079694293782f00f95c5dffaf39013a72e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0360301613037206$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24661662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22416522$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Folkert, Michael R., MD, PhD</creatorcontrib><creatorcontrib>Bilsky, Mark H., MD</creatorcontrib><creatorcontrib>Tom, Ashlyn K., BA</creatorcontrib><creatorcontrib>Oh, Jung Hun, PhD</creatorcontrib><creatorcontrib>Alektiar, Kaled M., MD</creatorcontrib><creatorcontrib>Laufer, Ilya, MD</creatorcontrib><creatorcontrib>Tap, William D., MD</creatorcontrib><creatorcontrib>Yamada, Yoshiya, MD</creatorcontrib><title>Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic radiosurgery (IG-SRS) may provide a more effective means of managing these lesions. Methods and Materials Patients with pathologically proven high-grade sarcoma metastatic to the spine treated with HF and SF IG-SRS were included. LC and overall survival (OS) were analyzed by the use of Kaplan-Meier statistics. Univariate and multivariate analyses were performed by the use of Cox regression with competing-risks analysis; all confidence intervals are 95%. Toxicities were assessed according to Common Terminology Criteria for Adverse Events, version 4.0. Results From May 2005 to November 11, 2012, 88 patients with 120 discrete metastases received HF (3-6 fractions; median dose, 28.5 Gy; n=52, 43.3%) or SF IG-SRS (median dose, 24 Gy; n=68, 56.7%). The median follow-up time was 12.3 months. At 12 months, LC was 87.9% (confidence interval [CI], 81.3%-94.5%), OS was 60.6% (CI, 49.6%-71.6%), and median survival was 16.9 months. SF IG-SRS demonstrated superior LC to HF IG-SRS (12-month LC of 90.8% [CI, 83%-98.6%] vs 84.1% [CI, 72.9%-95.3%] P =.007) and retained significance on multivariate analysis ( P =.030, hazard ratio 0.345; CI, 0.132-0.901]. Treatment was well tolerated, with 1% acute grade 3 toxicity, 4.5% chronic grade 3 toxicity, and no grade >3 toxicities. Conclusions In the largest series of metastatic sarcoma to the spine to date, IG-SRS provides excellent LC in the setting of an aggressive disease with low radiation sensitivity and poor prognosis. Single-fraction IG-SRS is associated with the highest rates of LC with minimal toxicity.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cohort Studies</subject><subject>Dose Fractionation</subject><subject>Female</subject><subject>HAZARDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Male</subject><subject>METASTASES</subject><subject>Middle Aged</subject><subject>MULTIVARIATE ANALYSIS</subject><subject>Neoplasm Metastasis</subject><subject>PATIENTS</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>RADIATION DOSES</subject><subject>Radiation Injuries - diagnosis</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOSENSITIVITY</subject><subject>Radiosurgery - adverse effects</subject><subject>Radiosurgery - methods</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy Dosage</subject><subject>RISK ASSESSMENT</subject><subject>Sarcoma - mortality</subject><subject>Sarcoma - pathology</subject><subject>Sarcoma - surgery</subject><subject>SARCOMAS</subject><subject>Spinal Neoplasms - mortality</subject><subject>Spinal Neoplasms - secondary</subject><subject>Spinal Neoplasms - surgery</subject><subject>SURGERY</subject><subject>TOXICITY</subject><subject>Treatment Outcome</subject><subject>VERTEBRAE</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkt-K1TAQxoMo7nH1DUQC3njTmqRN2t4Isuw_WFmwK3gXctLJ2dSepiapeHwH33nT7dELb4RAIPObbybzDUKvKckpoeJ9n9veu-2UM0KLnLKclOwJ2tC6arKC869P0YYUgmRFgk_QixB6QgilVfkcnbBSCCoE26Dft3PUbg8Bq7HDd-6n1TYesHEeXx0mZ7zS0bpRRegeidaOuwGyi-M7vt6rHWSXs-0S0Ebw4OIS0viz6qwLs9-BX_Va5VMlFfAniCqkY38lMRwdjveA28mO8BI9M2oI8Op4n6IvF-d3Z1fZze3l9dnHm0zzsowZ52ZLjAIDtAPFCaelUoIqxmugDaka0ZSsKaqaGUJMwzXvjFGmaNKkVMWgOEVvV10XopUhfRn0vXbjCDpKxkoqOGOJerdSk3ffZwhR7m3QMAxqBDcHSUVdiaqs6zqh5Ypq70LwYOTk7V75g6RELnbJXq52ycUuSZlMdqW0N8cK83YP3d-kP_4k4MMKQJrGDwt-aRZGDZ31S6-ds_-r8K-AHuxotRq-wQFC72Y_pklLKkNKkO2yMsvG0IIUFSOieADfmb8I</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Folkert, Michael R., MD, PhD</creator><creator>Bilsky, Mark H., MD</creator><creator>Tom, Ashlyn K., BA</creator><creator>Oh, Jung Hun, PhD</creator><creator>Alektiar, Kaled M., MD</creator><creator>Laufer, Ilya, MD</creator><creator>Tap, William D., MD</creator><creator>Yamada, Yoshiya, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20140401</creationdate><title>Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine</title><author>Folkert, Michael R., MD, PhD ; Bilsky, Mark H., MD ; Tom, Ashlyn K., BA ; Oh, Jung Hun, PhD ; Alektiar, Kaled M., MD ; Laufer, Ilya, MD ; Tap, William D., MD ; Yamada, Yoshiya, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-55fb0faefe1dea50514aa61a258e19079694293782f00f95c5dffaf39013a72e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cohort Studies</topic><topic>Dose Fractionation</topic><topic>Female</topic><topic>HAZARDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Male</topic><topic>METASTASES</topic><topic>Middle Aged</topic><topic>MULTIVARIATE ANALYSIS</topic><topic>Neoplasm Metastasis</topic><topic>PATIENTS</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>RADIATION DOSES</topic><topic>Radiation Injuries - diagnosis</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOSENSITIVITY</topic><topic>Radiosurgery - adverse effects</topic><topic>Radiosurgery - methods</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy Dosage</topic><topic>RISK ASSESSMENT</topic><topic>Sarcoma - mortality</topic><topic>Sarcoma - pathology</topic><topic>Sarcoma - surgery</topic><topic>SARCOMAS</topic><topic>Spinal Neoplasms - mortality</topic><topic>Spinal Neoplasms - secondary</topic><topic>Spinal Neoplasms - surgery</topic><topic>SURGERY</topic><topic>TOXICITY</topic><topic>Treatment Outcome</topic><topic>VERTEBRAE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Folkert, Michael R., MD, PhD</creatorcontrib><creatorcontrib>Bilsky, Mark H., MD</creatorcontrib><creatorcontrib>Tom, Ashlyn K., BA</creatorcontrib><creatorcontrib>Oh, Jung Hun, PhD</creatorcontrib><creatorcontrib>Alektiar, Kaled M., MD</creatorcontrib><creatorcontrib>Laufer, Ilya, MD</creatorcontrib><creatorcontrib>Tap, William D., MD</creatorcontrib><creatorcontrib>Yamada, Yoshiya, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Folkert, Michael R., MD, PhD</au><au>Bilsky, Mark H., MD</au><au>Tom, Ashlyn K., BA</au><au>Oh, Jung Hun, PhD</au><au>Alektiar, Kaled M., MD</au><au>Laufer, Ilya, MD</au><au>Tap, William D., MD</au><au>Yamada, Yoshiya, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>88</volume><issue>5</issue><spage>1085</spage><epage>1091</epage><pages>1085-1091</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic radiosurgery (IG-SRS) may provide a more effective means of managing these lesions. Methods and Materials Patients with pathologically proven high-grade sarcoma metastatic to the spine treated with HF and SF IG-SRS were included. LC and overall survival (OS) were analyzed by the use of Kaplan-Meier statistics. Univariate and multivariate analyses were performed by the use of Cox regression with competing-risks analysis; all confidence intervals are 95%. Toxicities were assessed according to Common Terminology Criteria for Adverse Events, version 4.0. Results From May 2005 to November 11, 2012, 88 patients with 120 discrete metastases received HF (3-6 fractions; median dose, 28.5 Gy; n=52, 43.3%) or SF IG-SRS (median dose, 24 Gy; n=68, 56.7%). The median follow-up time was 12.3 months. At 12 months, LC was 87.9% (confidence interval [CI], 81.3%-94.5%), OS was 60.6% (CI, 49.6%-71.6%), and median survival was 16.9 months. SF IG-SRS demonstrated superior LC to HF IG-SRS (12-month LC of 90.8% [CI, 83%-98.6%] vs 84.1% [CI, 72.9%-95.3%] P =.007) and retained significance on multivariate analysis ( P =.030, hazard ratio 0.345; CI, 0.132-0.901]. Treatment was well tolerated, with 1% acute grade 3 toxicity, 4.5% chronic grade 3 toxicity, and no grade >3 toxicities. Conclusions In the largest series of metastatic sarcoma to the spine to date, IG-SRS provides excellent LC in the setting of an aggressive disease with low radiation sensitivity and poor prognosis. Single-fraction IG-SRS is associated with the highest rates of LC with minimal toxicity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24661662</pmid><doi>10.1016/j.ijrobp.2013.12.042</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0360-3016 |
ispartof | International journal of radiation oncology, biology, physics, 2014-04, Vol.88 (5), p.1085-1091 |
issn | 0360-3016 1879-355X |
language | eng |
recordid | cdi_osti_scitechconnect_22416522 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adult Aged Aged, 80 and over Cohort Studies Dose Fractionation Female HAZARDS Hematology, Oncology and Palliative Medicine Humans Male METASTASES Middle Aged MULTIVARIATE ANALYSIS Neoplasm Metastasis PATIENTS Prognosis Proportional Hazards Models RADIATION DOSES Radiation Injuries - diagnosis Radiology RADIOLOGY AND NUCLEAR MEDICINE RADIOSENSITIVITY Radiosurgery - adverse effects Radiosurgery - methods RADIOTHERAPY Radiotherapy Dosage RISK ASSESSMENT Sarcoma - mortality Sarcoma - pathology Sarcoma - surgery SARCOMAS Spinal Neoplasms - mortality Spinal Neoplasms - secondary Spinal Neoplasms - surgery SURGERY TOXICITY Treatment Outcome VERTEBRAE |
title | Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T13%3A49%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20and%20Toxicity%20for%20Hypofractionated%20and%20Single-Fraction%20Image-Guided%20Stereotactic%20Radiosurgery%20for%20Sarcomas%20Metastasizing%20to%20the%20Spine&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Folkert,%20Michael%20R.,%20MD,%20PhD&rft.date=2014-04-01&rft.volume=88&rft.issue=5&rft.spage=1085&rft.epage=1091&rft.pages=1085-1091&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2013.12.042&rft_dat=%3Cproquest_osti_%3E1687674888%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1687674888&rft_id=info:pmid/24661662&rft_els_id=1_s2_0_S0360301613037206&rfr_iscdi=true |